Flagship Harbor Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Flagship Harbor Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-900	Closed	-$6K	–	2221
2020 Q1	$6K	Buy	900 +400	+80%	+$4.99K	﹤0.01%	1397
2019 Q4	$12K	Hold	500	–	–	﹤0.01%	1294
2019 Q3	$13K	Hold	500	–	–	﹤0.01%	1233
2019 Q2	$13K	Hold	500	–	–	﹤0.01%	1225
2019 Q1	$17K	Hold	500	–	–	﹤0.01%	1141
2018 Q4	$9K	Hold	500	–	–	﹤0.01%	1284
2018 Q3	$12K	Buy	+500	New	+$16.3K	﹤0.01%	1357

Other funds holding PTLA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

WIC

Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return

Flagship Harbor Advisors's PTLA Position: Q2 2020 in Review

Flagship Harbor Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2020, closing a stake of 900 shares — an estimated $6K sold.

Flagship Harbor Advisors first reported a position in PTLA in Q3 2018 and held it in 7 quarters. The position peaked at $17K in Q1 2019. 162 funds tracked by Wall St. Rank hold PTLA as of Q2 2020.

Flagship Harbor Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Flagship Harbor Advisors sold 900 Portola Pharmaceuticals, Inc. shares in Q2 2020, an estimated $6K.
Flagship Harbor Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q3 2018 and held it in 7 quarters.
Flagship Harbor Advisors's Portola Pharmaceuticals, Inc. position peaked at $17K in Q1 2019.
162 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2020.

Based on Flagship Harbor Advisors's 13F filing for Q2 2020, filed 31 Jul 2020.